101.64

0.54% -0.55

Ligand Pharmaceuticals Inc (LGND)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Ligand Pharmaceuticals Inc stock is traded at $101.64, with a volume of 99,876. It is down -0.54% in the last 24 hours and down -7.08% over the past month. Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Previous Close:

$102.19

Open:

$102.51

24h Volume:

99,876

Relative Volume:

0.83

Market Cap:

$1.96B

Revenue:

$152.42M

Net Income/Loss:

$45.24M

P/E Ratio:

40.49

EPS:

2.51

Net Cash Flow:

$6.97M

1W Performance:

+0.04%

1M Performance:

-7.08%

6M Performance:

-17.16%

1Y Performance:

+19.51%

1-Day Range:

$100.67

$103.79

1-Week Range:

$98.89

$104.01

52-Week Range:

$77.42

$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name

Ligand Pharmaceuticals Inc

Sector

Healthcare (1166)

Industry

Biotechnology (665)

Phone

858-550-7500

Address

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Employee

Twitter

@Ligand_LGND

Next Earnings Date

2025-02-18

Latest SEC Filings

LGND's Discussions on Twitter

Compare LGND with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGND Ligand Pharmaceuticals Inc	101.64	1.96B	152.42M	45.24M	6.97M	2.51
ONC Beone Medicines Ltd Adr	245.93	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.43	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.415	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.10	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.81	65.13B	14.09B	4.50B	2.96B	39.28

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Initiated	Stifel	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Resumed	Stephens	Overweight
Feb-04-21	Reiterated	H.C. Wainwright	Buy
Oct-06-20	Initiated	Barclays	Overweight
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-03-19	Reiterated	H.C. Wainwright	Buy
Mar-06-19	Reiterated	H.C. Wainwright	Buy
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy
Sep-11-18	Reiterated	Argus	Buy
Aug-17-18	Initiated	Goldman	Neutral
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy
Dec-27-17	Reiterated	H.C. Wainwright	Buy
Sep-05-17	Resumed	H.C. Wainwright	Buy
Oct-05-16	Reiterated	H.C. Wainwright	Buy
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell
Mar-11-16	Initiated	Sidoti	Buy
Mar-03-16	Initiated	H.C. Wainwright	Buy

View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

May 29, 2025

BNP Paribas Financial Markets Cuts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

May 29, 2025

May 26, 2025

Lazard Asset Management LLC Sells 1,507 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

May 26, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 26, 2025

May 23, 2025

Bank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

May 23, 2025

May 20, 2025

Executives At Ligand Pharmaceuticals Show Confidence With Major Stock Buys - Finimize

May 20, 2025

Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

May 20, 2025

Ameriprise Financial Inc. Raises Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

May 20, 2025

May 19, 2025

Ligand Rings the Nasdaq Stock Market Opening Bell - Nasdaq

May 19, 2025

May 16, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 16, 2025

May 14, 2025

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 - TradingView

May 14, 2025

The Manufacturers Life Insurance Company Buys 779 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

May 14, 2025

May 13, 2025

Ligand Pharmaceuticals Executives Increase Holdings - TradingView

May 13, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.com - Defense World

May 13, 2025

May 12, 2025

LGND: 1Q:25 Results - MSN

May 12, 2025

May 11, 2025

Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

May 11, 2025

May 10, 2025

Oppenheimer Maintains Rating and Raises Price Target for LGND | - GuruFocus

May 10, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025

Oppenheimer Maintains Rating and Raises Price Target for LGND | LGND Stock News - GuruFocus

May 09, 2025

Oppenheimer Raises Price Target for Ligand (LGND) to $145 | LGND Stock News - GuruFocus

May 09, 2025

Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating - marketscreener.com

May 09, 2025